Responses
E-Poster viewings
Ovarian Cancer
IGCS19-0649
302 A phase IB study of indirect immunization with Oregovomab and TLR3 stimulation with hiltonol® (H) in patients with recurrent platinum resistant ovarian cancer (PROC)
Compose a Response to This Article
Other responses
No responses have been published for this article.